Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

IMI moves forward

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Sinha, G. Nat. Biotechnol. 29, 473 (2011).

    Article  PubMed  Google Scholar 

  2. Editorial. Nat. Biotechnol. 29, 551 (2011).

  3. Abbott, A. Nature 468, 158–159 (2010).

    Article  PubMed  Google Scholar 

  4. Matheis, K.J. et al. Drug Discov. Today (in press).

  5. Obiol-Pardo, C., Gomis-Tena, J., Ferran Sanz, F., Saiz, F. & Pastor, M. J. Chem. Inf. Model. 51, 483–492 (2011).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Ethics declarations

Competing interests

S.C. is with Novartis, R.D. is with UCB, P.H.A. is with Lundbeck and C.I. is with Genzyme.

Additional information

Correspondence should be addressed to Michel Goldman, Executive Director, Innovative Medicines Initiative (IMI), Brussels, Belgium. e-mail:

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strohmeier, R., Draghia-Akli, R., Rys, A. et al. IMI moves forward. Nat Biotechnol 29, 689–690 (2011).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research